Vetsys Pharmaceutical
Vetsys Pharmaceutical
In the evolving global pharmaceutical market, Sustained-Release (SR) tablets have emerged as a pinnacle of patient compliance and therapeutic efficacy. As a leading hub for chemical and pharmaceutical innovation, China has established itself as the premier destination for high-quality SR formulation manufacturing. This white paper explores why top global enterprises are shifting their procurement strategies toward Chinese experts like Zhengzhou Vetsys Pharmaceutical Co., Ltd.
Established in 2005, Zhengzhou Vetsys Pharmaceutical Co., Ltd. (Vetsys) is a titan in the animal pharmaceutical industry. With a registered capital of 30 million RMB, we have spent nearly two decades refining the science of drug delivery. Our facility isn't just a factory; it's a specialized hub comprising workshops for powders, injections, oral solutions, and most notably, advanced sustained-release granules and tablets.
Compliance is our cornerstone. Operating under strict Good Manufacturing Practices (GMP), we ensure every tablet leaving our line meets international safety standards. By 2015, Vetsys achieved annual domestic sales exceeding USD 20 million, a testament to our reliability and authority in the Chinese market.
China invests billions into polymer science, enabling the creation of complex matrix and reservoir systems for controlled drug release.
Massive production capacity ensures that global demand is met without compromising on lead times or quality consistency.
Leveraging a complete upstream chemical supply chain allows Chinese factories to offer competitive pricing for premium formulations.
Strategically located near major shipping hubs like Qingdao and Shanghai, ensuring seamless export to over 100 countries.
Vetsys distinguishes itself from competitors by placing a strong emphasis on technological development and continuous innovation. We have established an independent research institute equipped with five specialized laboratories and a team of world-class scientists. This enables us to quickly adapt to market demands and produce cutting-edge solutions for animal health.
Our research focuses on pharmacokinetic optimization, ensuring that active ingredients are released at a steady rate, reducing dosing frequency and minimizing side effects in livestock and companion animals.
Using machine learning to predict dissolution profiles and optimize polymer ratios for specific animal species.
Transitioning toward biodegradable delivery vehicles to minimize environmental residue in soil and water.
Integration of NFC and QR technology for track-and-trace capabilities, ensuring anti-counterfeiting and safety.
Injection Molding: Precision engineering for dosing tools and delivery devices.
Blow Molding: High-speed production of sterile containers and liquid drug housings.
Extrusion Molding: Continuous processing for uniform granule and tablet precursors.
Processing: Specialized hygienic handling for diagnostic and application tools.
Controlled Drying: Moisture control is vital for sustained-release tablet stability.
Global pharmaceutical buyers look for more than just a product; they seek a strategic partner. Vetsys offers End-to-End Solutions:
As part of our vision, we are actively exploring international expansion, aiming to bring high-quality, innovative animal health solutions to global markets through partnerships and research collaborations.
